Towards personalized treatment in multiple myeloma based on molecular characteristics

Charlotte Pawlyn and Faith E. Davies


To date, the choice of therapy for an individual multiple myeloma patient has been based on clinical factors such as age and co-morbidities. The widespread evolution, validation and clinical utilization of molecular technologies, such as fluorescent in-situ hybridization and next generation sequencing has enabled the identification of a number of prognostic and predictive biomarkers for progression free, overall survival and treatment response. In this review we argue that in order to continue to improve myeloma patient outcomes incorporating such biomarkers into the routine diagnostic workup of patients will allow for the use of personalized, biologically based treatments.

  • Submitted September 25, 2018.
  • Accepted October 30, 2018.